Cellectis Starts BPDCN Phase I Trial with Gene-Edited CAR-T Therapy – Genetic Engineering & Biotechnology News
|
Cellectis Starts BPDCN Phase I Trial with Gene-Edited CAR–T Therapy
Genetic Engineering & Biotechnology News Cellectis reported that the first patient has been dosed in a Phase I clinical trial evaluating its TALEN® gene-edited CAR T-cell product UCART123 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). The BPDCN study follows on from … |
